CD147 and Prostate Cancer: A Systematic Review and Meta-Analysis

Background
Prostate cancer is one of the most common non-cutaneous malignancies in men. We aimed to systemically evaluate the relationship between the expression of CD147 in tissues and the clinicopathological features of prostate cancer.
Methods and Findings
PubMed (1966–2016), EMBASE (1980–2016), the Cochrane Library (1996–2016), Web of Science (1945–2016), China National Knowledge Infrastructure (1982–2016), and the WanFang databases (1988–2016) were searched. Literature quality assessment was performed with the Newcastle-Ottawa Scale. Meta-analysis was performed by using Review Manager 5.3 and Stata 13.0. A total of 12591 prostate cancer patients from 14 studies were included. The results of the meta-analysis showed that there were significant differences in the positive expression rate in the following comparisons: prostatic cancer tissues vs. normal prostate tissues (odds ratio [OR] = 26.93, 95% confidence interval [CI] 7.95–91.20, P < 0.00001), prostatic cancer tissues vs. benign prostatic hyperplasia tissues (OR = 20.54, 95% CI 8.20–51.44, P < 0.00001), high Gleason score vs. low Gleason score (OR = 2.39, 95% CI 1.33–4.27, P = 0.03), TNM III to IV vs. TNM I to II (OR = 9.95, 95% CI 4.96–19.96, P < 0.00001), low or moderate differentiation vs. high differentiation (OR = 8.12, 95% CI 3.69–17.85, P < 0.00001), lymph node metastasis vs. non-lymph node metastasis (OR = 4.31, 95% CI 1.11–16.71, P = 0.03), and distant metastasis vs. non-distant metastasis (OR = 8.90, 95% CI 3.24–24.42, P < 0.00001).
Conclusion
The CD147 positive expression rate was closely related to the clinical characteristics of prostate cancer, but more research is needed to confirm the findings owing to the results of the subgroups.

背景
前列腺癌是男性最常见的非皮肤恶性肿瘤之一。本研究旨在系统评估组织中CD147的表达与前列腺癌临床病理特征之间的关联。
方法与结果
检索了PubMed（1966–2016）、EMBASE（1980–2016）、Cochrane图书馆（1996–2016）、Web of Science（1945–2016）、中国知网（China National Knowledge Infrastructure）（1982–2016）以及万方数据库（1988–2016）的相关文献。采用纽卡斯尔-渥太华量表（Newcastle-Ottawa Scale）进行文献质量评价。使用Review Manager 5.3与Stata 13.0软件开展Meta分析。最终纳入14项研究，共计12591例前列腺癌患者。Meta分析结果显示，以下各组对比的阳性表达率存在显著统计学差异：前列腺癌组织与正常前列腺组织（比值比[odds ratio, OR]=26.93，95%置信区间[confidence interval, CI] 7.95–91.20，P<0.00001）；前列腺癌组织与良性前列腺增生组织（OR=20.54，95%CI 8.20–51.44，P<0.00001）；高格里森评分（Gleason score）组与低格里森评分组（OR=2.39，95%CI 1.33–4.27，P=0.03）；TNM分期Ⅲ~Ⅳ期与Ⅰ~Ⅱ期（OR=9.95，95%CI 4.96–19.96，P<0.00001）；中低分化组与高分化组（OR=8.12，95%CI 3.69–17.85，P<0.00001）；伴淋巴结转移组与无淋巴结转移组（OR=4.31，95%CI 1.11–16.71，P=0.03）；伴远处转移组与无远处转移组（OR=8.90，95%CI 3.24–24.42，P<0.00001）。
结论
CD147阳性表达率与前列腺癌的临床特征密切相关，但鉴于亚组分析结果，仍需开展更多研究以验证本研究发现。